Curriculum Vitae

Personal Information:

- Forename: Ali
- Surname: Jahanian-Najafabadi
- Date and Place of Birth: 1982- Najafabad, Isfahan.
- Languages: Persian (Native), English (Fluent), German, French (Elementary)

Contact Information:

- Present Address: Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences and Health Services, Hezar Jarib Ave. Isfahan, Iran.
- Tel: +98 313 7927056
- Fax: +98 313 6680011
- Email: jahanian@pharm.mui.ac.ir; ajnajafabadi@yahoo.com

Current Affiliation:

- Professor; Department of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran.

Education and trainings:

- Nov 2018-Sep 2019: Sabbatical leave at University of Waterloo, Waterloo, ON. Canada
- 2006- 2012: Ph.D. of Pharmaceutical Biotechnology, Pasteur Institute of Iran, Tehran, Iran.
- 2000-2006: Doctor of Pharmacy (Pharm. D.), School of Pharmacy, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran.
- **Ph. D. Thesis**
  - **Expression of A1-GMCSF fusion protein in Baculovirus expression system for biotherapy of hematologic malignancies.** Supervisors: Saeid Bouzari (Ph.D.), Mana Oloomi (Ph.D.)

Pharm. D. Thesis:

- **Cloning of Polyhydroxyalkanoate Synthase Genes of *Pseudomonas aeroginusa* PTCC 1310.** Supervisors: Daryoush Abedi (Ph.D), Hamid Mir Mohammad Sadeghi (Ph.D), Sadegh Valian Boroujeni (Ph.D).

- **Selected Papers:**

1. Human umbilical cord-derived mesenchymal stem cells-harvested mitochondrial transplantation improved motor function in TBI models through rescuing neuronal cells from apoptosis and alleviating astrogliosis and microglia activation. Bamshad C, Habibi Roudkenar M, Abedinzade M, Yousefzadeh Chabok S, Pourmohammadi-Bejarpasi Z, Najafi-Ghalehlou N, Sato T, Tomita K, **Jahanian-Najafabadi A**, Feizkhah A, Mohammadi Roushandeh A. Int Immunopharmacol. 2023 May;118:110106.
2. Novel N-α-amino acid spacer-conjugated phthalimide-triazine derivatives: synthesis, antimicrobial and molecular docking studies. Asadi P, Khodamoradi E, Khodarahmi G, **Jahanian-Najafabadi A**, Marvi H, Dehghan Khalili S. Amino Acids. 2023 Mar;55(3):337-348.
3. Combination Therapy of Metadichol Nanogel and Lipocalin-2 Engineered Mesenchymal Stem Cells Improve Wound Healing in Rat Model of Excision Injury. Pourmohammadi-Bejarpasi Z, Sabzevari R, Mohammadi Roushandeh A, Ebrahimi A, Mobayen M, **Jahanian-Najafabadi A**, Darjani A, Habibi Roudkenar M. Adv Pharm Bull. 2022 May;12(3):550-560.
4. Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin. Havaei SM, Aucoin MG, **Jahanian-Najafabadi A**. Front Oncol. 2021 Dec 16;11:781800.
5. SA/G hydrogel containing NRF2-engineered HEK-293-derived CM improves wound healing efficacy of WJ-MSCs in a rat model of excision injury. Sabzevari R, Mohammadi Roushandeh A, Alijani-Ghazyani Z, **Jahanian-Najafabadi A**, Habibi Roudkenar M. J Tissue Viability. 2021 Nov;30(4):527-536.
6. Design and production of new chimeric reteplase with enhanced fibrin affinity: a theoretical and experimental study. Mohammadi E, Mahnam K, **Jahanian-Najafabadi A**, Sadeghi HMM. J Biomol Struct Dyn. 2021 Mar;39(4):1321-1333.
7. Expressing of Recombinant VEGFR2-specific Nanobody in Baculovirus Expression System. Shokrollahi N, Habibi-Anbouhi M, **Jahanian-Najafabadi A**, Alirahimi E, Behdani M. Iran J Biotechnol. 2021 Jan 1;19(1):e2783.
8. Generation of HBsAg DNA aptamer using modified cell-based SELEX strategy. Mirian M, Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Darzi L, Taghizadeh R, **Jahanian-Najafabadi A**, Khanahmad H. Mol Biol Rep. 2021 Jan;48(1):139-146.

9. Conditioned medium harvested from Hif1α engineered mesenchymal stem cells ameliorates LAD-occlusion -induced injury in rat acute myocardial ischemia model. Alijani-Ghazyani Z, Roushandeh AM, Sabzevari R, Salari A, Razavi Toosi MT, **Jahanian-Najafabadi A**, Roudkenar MH. Int J Biochem Cell Biol. 2021 Jan;130:105897.
10. Mesenchymal stem cells-derived mitochondria transplantation mitigates I/R-induced injury, abolishes I/R-induced apoptosis, and restores motor function in acute ischemia stroke rat model. Pourmohammadi-Bejarpasi Z, Roushandeh AM, Saberi A, Rostami MK, Toosi SMR, **Jahanian-Najafabadi A**, Tomita K, Kuwahara Y, Sato T, Roudkenar MH. Brain Res Bull. 2020 Dec;165:70-80.
11. Optimization of solvent media to solubilize TEV protease using response surface method. Mohammadian N, Mohammadian H, Moazen F, Pakdel MH, **Jahanian-Najafabadi A**, Mir Mohammad Sadeghi H. Res Pharm Sci. 2020 Aug 28;15(4):331-339.
12. Evaluation of soluble expression of recombinant granulocyte macrophage stimulating factor (rGM-CSF) by three different E. coli strains. Soheili S, Jahanian-Najafabadi A, Akbari V. Res Pharm Sci. 2020 Jul 3;15(3):218-225.
13. Optimization of Buffer Additives for Efficient Recovery of hGM-CSF from Inclusion Bodies Using Response Surface Methodology. Ahmadian M, **Jahanian-Najafabadi A**, Akbari V. Iran J Pharm Res. 2020 Summer;19(3):297-309.
14. Transfer of healthy fibroblast-derived mitochondria to HeLa ρ0 and SAS ρ0 cells recovers the proliferation capabilities of these cancer cells under conventional culture medium, but increase their sensitivity to cisplatin-induced apoptotic death. Roushandeh AM, Tomita K, Kuwahara Y, **Jahanian-Najafabadi A**, Igarashi K, Roudkenar MH, Sato T. Mol Biol Rep. 2020 Jun;47(6):4401-4411.
15. Evaluation of cytotoxic and apoptotic effects of DT386-BR2: A promising anticancer fusion protein Shafiee, F., Rabbani, M., **Jahanian-Najafabadi, A.** Journal of Reports in Pharmaceutical Sciences, 2020, 9(1), pp. 68–72
16. In silico design of two novel fusion proteins, p28-IL-24 and p28-M4, targeted to breast cancer cells. Ghavimi R, Mohammadi E, Akbari V, Shafiee F, **Jahanian-Najafabadi A.** Res Pharm Sci. 2020 May 11;15(2):200-208.
17. Transplantation of Umbilical Cord-Derived Mesenchymal Stem Cells Overexpressing Lipocalin 2 Ameliorates Ischemia-Induced Injury and Reduces Apoptotic Death in a Rat Acute Myocardial Infarction Model. Alijani-Ghazyani Z, Sabzevari R, Roushandeh AM, **Jahanian-Najafabadi A,** Amiri F, Roudkenar MH. Stem Cell Rev Rep. 2020 Jul 12. doi: 10.1007/s12015-020-10007-8.
18. Mitochondrial transplantation ameliorates ischemia/reperfusion-induced kidney injury in rat. Hanieh Jabbari, Amaneh Mohammadi Roushandeh, Mojdeh Kheirandish Rostami, Mohammad Taghi Razavi-Toosi, Mohammad Ali Shokrgozar, **Ali Jahanian-Najafabadi**, Yoshikazu Kuwahara, Mehryar Habibi Roudkenar. Biochimica et

Biophysica Acta (BBA)-Molecular Basis of Disease. Volume 1866, Issue 8, 1 August 2020, 165809

19. RGD peptide grafted polybutylene adipate-co-terephthalate/gelatin electrospun nanofibers loaded with a matrix metalloproteinase inhibitor drug for alleviating of wounds: an in vitro/in vivo study. Jaleh Varshosaz, Khatereh Arabloo, Nasim Sarrami, Erfaneh Ghassami, Emadeddin Yazdani Kachouei, Monireh Kouhi & **Ali Jahanian-Najafabadi**. Drug Development and Industrial Pharmacy.46 (3), 3 March 2020, Pages 484-497
20. Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types. Sina Rahimi, Amaneh Mohammadi Roushandeh, Ebrahim Ahmadzadeh, **Ali Jahanian-Najafabadi** & Mehryar Habibi Roudkenar. Mol Biol Rep 47, 2327–2346 (2020).
21. Mitochondrial characteristics contribute to proliferation and migration potency of MDA-MB-231 cancer cells and their response to cisplatin treatment. Mojdeh Kheirandish-Rostami, Mehryar Habibi Roudkenar, **Ali Jahanian-Najafabadi**, Kazuo Tomita, Yoshikazu Kuwahara, Tomoaki Sato, Amaneh Mohammadi Roushandeh. Life Sciences, 244, 1 March 2020, 117339
22. Expression and one step intein-mediated purification of biologically active human G-CSF in Escherichia coli. Sima, S., Shafiee, F., **Jahanian-Najafabadi, A.** Mol Biol Rep 47, 2861–2869 (2020)
23. Targeted Diphtheria Toxin-Based Therapy: A Review Article. Shafiee, F., Aucoin, M.G., **Jahanian-Najafabadi, A**. Frontiers in Microbiology. 10: 18 October 2019, Article number 2340
24. Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity. Sadeghian-Rizi, T, Behdani, M, Khanahmad, H, Ghasemi-Dehkordi, P, Mirmohammad Sadeghi, H, **Jahanian-Najafabadi, A**. International Journal of Peptide Research and Therapeutics. Volume 25, Issue 2, 1 June 2019, Pages 535-540.
25. HER-2 aptamer-targeted Ecoflex® nanoparticles loaded with docetaxel promote breast cancer cells apoptosis and anti-metastatic effect. Ghassami E, Varshosaz J, Mirian M, **Jahanian-Najafabadi A**. IET Nanobiotechnol. 2019; 13(4):428-434.
26. A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines. Soleimani, M Sadeghi, HM; **Jahanian-Najafabadi, A**. Iran J Pharm Res. 2019 Spring: 18(2): 735-744
27. High-yield Production of Granulocyte-macrophage Colony-stimulating Factor in E. coli BL21 (DE3) By an Auto-induction Strategy. Malekian R**, Jahanian-Najafabadi A**, Moazen F, Ghavimi R, Mohammadi E, Akbari V. Iran J Pharm Res. 2019 Winter;18(1):469-478.

28. Improvement of soluble expression of GM-CSF in the cytoplasm of *Escherichia coli* using chemical and molecular chaperones. Malekian R, Sima S, **Jahanian-Najafabadi A,** Moazen F, Akbari V. Protein Expr Purif. 2019; 160:66-72.
29. Generation and Characterization of a Functional Nanobody against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis. Sadeghian-Rizi T, Behdani M, Khanahmad H, Sadeghi HM, **Jahanian-Najafabadi A**. CNS Neurol Disord Drug Targets. 2019;18(2):141-148.
30. Preparation and Characterization of Spray-Dried Inhalable Powders Containing Polymeric Micelles for Pulmonary Delivery of Paclitaxel in Lung Cancer. Rezazadeh M, Davatsaz Z, Emami J, Hasanzadeh F, **Jahanian-Najafabadi A**. J Pharm Pharm Sci. 2018;21(1s):200s-214s.
31. Chronic Oral Arsenic Exposure and Its Correlation with Serum S100B Concentration. Golmohammadi J, **Jahanian-Najafabadi A**, Aliomrani M. Biol Trace Elem Res. 2019 May;189(1):172-179.
32. A-NGR fusion protein induces apoptosis in human cancer cells. Mohammadi-Farsani A, Habibi-Roudkenar M, Golkar M, Shokrgozar MA, **Jahanian-Najafabadi A**, KhanAhmad H, Valiyari S, Bouzari S. EXCLI J. 2018 Jun 25;17:590-597.
33. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study. Varshosaz J, Taymouri S, **Jahanian-Najafabadi A**, Alizadeh A. IET Nanobiotechnol. 2018 Sep;12(6):795-806.

    Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges. Sadeghian-Rizi T, Khanahmad H, **Jahanian-Najafabadi A**. CNS Neurol Disord Drug Targets. 2018;17(7):496-508.
34. Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin-Induced Genotoxicity. Sadeghi F, Etebari M, Habibi Roudkenar M, **Jahanian-Najafabadi A**. Iran J Pharm Res. 2018 Winter;17(1):147-154.
35. Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex® nanoparticles for docetaxel delivery in ovarian cancer. Ghassami E, Varshosaz J, **Jahanian-Najafabadi A**, Minaiyan M, Rajabi P, Hayati E. Int J Nanomedicine. 2018 Jan 23;13:493-504.
36. Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles. Varshosaz J, Ziaei V, Minaiyan M, **Jahanian-Najafabadi A**, Sayed-Tabatabaei L. Pharm Dev Technol. 2019 Feb;24(2):133-144.
37. A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation. Emami J, Rezazadeh M, Mashayekhi M, Rostami M, **Jahanian-Najafabadi A**. Drug Dev Ind Pharm. 2018 May;44(5):729-740.
38. Transferrin-targeted poly(butylene adipate)/terephthalate nanoparticles for targeted delivery of 5-fluorouracil in HT29 colorectal cancer cell line. Varshosaz, J. Riahi, S.

Ghassami, E. **Jahanian-Najafabadi, A**. Journal of Bioactive and Compatible Polymers. Volume 32, Issue 5, 1 September 2017, Pages 503-527

39. Cloning, Expression, and Assessment of Cytotoxic Effects of A-NGR Fusion Protein. Mohammadi-Farsani, A. **Jahanian-Najafabadi, A.** Habibi-Roudkenar, M. Golkar, M. Shokrgozar, M.A. KhanAhmad, H. Golshani, M. Valiyari, S. Bouzari, S. International Journal of Peptide Research and Therapeutics. 14 August 2017, Pages 1-7
40. In-vivo evaluation of DT386-BR2, a promising anticancer fusion protein, in mice model. Shafiee, F.Enteshari, R. Rabbani, M. **Jahanian-Najafabadi, A.** Journal of Isfahan Medical School. Volume 35, Issue 433, August 2017, Pages 655-661

41. Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model. Roudkenar, M.H.Halabian, R. Tehrani, H.A. Amiri, F. **Jahanian-Najafabadi, A**. Roushandeh, A.M.Abbasi-Malati, Z. Kuwahara, Y. Cytotechnology. 2 June 2017, Pages 1-15
42. Recombinant Production and Intein-Mediated Purification of an Antimicrobial Peptide, BR2. Shafiee, F., Minaiyan, G., Moazen, F., **Jahanian-Najafabadi, A**. International Journal of Peptide Research and Therapeutics. Volume 23, Issue 4, 1 December 2017, Pages 501-507
43. Artificial Blood Substitutes: First Steps on the Long Route to Clinical Utility. Samira Moradi, **Ali Jahanian-Najafabadi** and Mehryar Habibi Roudkenar. Clinical Medicine Insights: Blood Disorders 2016:9 33-41
44. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. Shafiee F, Rabbani M, **Jahanian-Najafabadi A.** J Microbiol Methods. 2016 Nov;130:100-105
45. Expression and purification of toxic anti-breast cancer p28-NRC chimeric protein. Soleimani M, Mirmohammad-Sadeghi H, Sadeghi-Aliabadi H, **Jahanian-Najafabadi A**. Adv Biomed Res. 2016 Apr 19;5:70.
46. Luteinizing hormone-releasing hormone targeted poly(methyl vinyl ether maleic acid) nanoparticles for doxorubicin delivery to MCF-7 breast cancer cells. Varshosaz, J., **Jahanian-Najafabadi, A.**, Ghazzavi, J. IET Nanobiotechnology, Volume 10, Issue 4, Pages 206-21
47. Targeted Delivery of Docetaxel by Use of Transferrin/Poly(allylamine hydrochloride)-functionalized Graphene Oxide Nanocarrier. Nasrollahi, F., Varshosaz, J., Khodadadi, A.A., Lim, S., **Jahanian-Najafabadi, A**. ACS Applied Materials and Interfaces, Volume 8, Issue 21, Pages 13282-13293
48. Theoretical design of a new chimeric protein for the treatment of breast cancer. Soleimani, M., Mahnam, K., Mirmohammad-Sadeghi, H., Sadeghi-Aliabadi, H., **Jahanian-Najafabadi, A**. Research in Pharmaceutical Sciences, Volume 11, Issue 3, 2016, Pages 187-199

49. Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury. Mohammadzadeh-Vardin, M.a, Roudkenar, M.H.b , **Jahanian-Najafabadi, A**. Advanced Pharmaceutical Bulletin, Volume 5, Issue 2, 2015, Pages 201-20
50. In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments: In vitro augmentation of mesenchymal stem cells viability. Amiri F, **Jahanian-Najafabadi A**, Roudkenar MH. Cell Stress Chaperones. 2015 Mar;20(2):237-51.
51. Antigenicity and immunogenicity of fused B-subunit of heat labile toxin of Escherichia coli and colonization factor antigen I polyepitopes. Savar NS, Dashti A, Darzi Eslam E, **Jahanian-Najafabadi A**, Jafari A. J Microbiol Methods. 2014 Nov;106:40-6.
52. Adenovirus-mediated over-expression of Nrf2 within mesenchymal stem cells (MSCs) protected rats against acute kidney injury. Mohammadzadeh-Vardin, M., Roudkenar, M.H., **Jahanian-Najafabadi, A.** Adv. Pharm. Bulletin. 2015; 5 (2), pp. 201-208.
53. Co-culture of bone marrow-derived mesenchymal stem cells overexpressing lipocalin 2 with HK-2 and HEK293 cells protects the kidney cells against cisplatin-induced injury. Halabian R, Roudkenar MH, **Jahanian-Najafabadi A**, Hosseini KM, Tehrani HA. Cell Biol Int. 2015 Feb;39(2):152-63.
54. Molecualr cloning of the capsular antigen F1 of Yersinia pestis in pBAD/gIII plasmid. **Jahanian-Najafabadi, A.**, Soleimani, M., Azadmanesh, K., Mostafavi, E., Majidzadeh-A, K. Res. Pharm. Sci. 2015; 10 (1), pp. 91-96
55. Recombinant human lipocalin 2 acts as an antibacterial agent to prevent platelet contamination. Bakhshandeh Z, Halabian R, Imani-Fooladi AA, **Jahanian-Najafabadi A**, Jalili MA, Roudkenar MH. Hematology. 2014 Dec;19(8):487-92.
56. In silico and In vivo studies of truncated forms of flagellin (FliC) of enteroaggregative *Escherichia coli* fused to FimH from uropathogenic *Escherichia coli* as a vaccine candidate against urinary tract infections. Savar NS, **Jahanian-Najafabadi A**, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. J Biotechnol. 2014 Apr 10;175:31-7.
57. Induction of multipotency in umbilical cord-derived mesenchymal stem cells cultivated under suspension conditions. Amiri F, Halabian R, Salimian M, Shokrgozar MA, Soleimani M, **Jahanian-Najafabadi A**, Roudkenar MH. Cell Stress Chaperones. 2014 Sep;19(5):657-66.
58. Lipocalin 2 decreases senescence of bone marrow-derived mesenchymal stem cells under sub-lethal doses of oxidative stress. Bahmani B, Roudkenar MH, Halabian R, **Jahanian-Najafabadi A**, Amiri F, Jalili MA. Cell Stress Chaperones. 2014 Sep;19(5):685-93.
59. In silico and in vitro study of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli (EAEC), Savar NS, Sardari S, **Jahanian-Najafabadi A** and Bouzari S. Mol. Inf. 2013, 32, 707 – 716.

60. Lipocalin-2 mediated up-regulation of various antioxidants and growth factors protects bone-marrow derived mesenchymal stem cells against unfavorable microenvironments, Raheleh Halabian, Hossein A. Tehrani, **Ali Jahanian-Najafabadi**, Mehryar Habibi Roudkenar. Cell Stress Chaperones. 2013 Nov;18(6):785-800.
61. Adenovirus-mediated over-expression of the Nrf2 protein within MSCs protected rats against acute kidney injury, Mohammadzadeh M, Habibi Roudkenar M, **Ali Jahanian-Najafabadi**. Adv Pharm Bull. 2015 Jun; 5(2):201-8.

62. HIF-1α confers resistance to induced stress in bone marrow-derived mesenchymal stem cells, Ali Asghar Kiani, Ahmad Kazemi, Rahele Halabian, Mahshid ohammadipour, **Ali Jahanian-Najafabadi**, Mehryar Habibi Roudkenar. Arch. Med. Res., 2013. 44 (2013) 185-193
63. Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system, S Aflakiyan, H Mir Mohammad Sadeghi, MA Shokrgozar, M Rabbani, S Bouzari, **A Jahnian-Najafabadi**, Research in Pharmaceutical Sciences 2013; 8(1): 9-15.
64. Isolation, Cloning and High- Level Expression of Neutrophil Gelatinase-Associated Lipocalin Lipocalin2 by Baculovirus Expression System through Gateway Technology. Mahdi Rouhbakhsh, Raheleh Halabian, Nasser Masroori , Mahshid Mohammadi Pour, Parisa Bahmani, Amaneh Mohammadi Roushandeh**, Ali Jahanian-Najafabadi**, Mehryar Habibi Roudkenar. Iranian Journal of Basic Medical Sciences. 2012; 3(56): 845-852.
65. Optimization of the Expression of Genes Encoding Poly (3-hydroxyalkanoate) Synthase from Pseudomonas aeruginosa PTCC 1310 in Escherichia coli. Daryoush Abedi, Maryam Beheshti, **Ali Jahanian-Najafabadi**, Hamid Mir Mohammad Sadeghi and Vajihe Akbari. Avicenna J Med Biotech 2012; 4(1): 47-51.
66. Attempts to Express the A1-GMCSF Immunotoxin in the Baculovirus Expression Vector System. **Ali Jahanian-Najafabadi**, Saeid Bouzari, Mana Oloomi, Mehryar Habibi Roudkenar, and Lorenz M. Mayr. Biosci, Biotechnol, Biochem. 2012. 76(4).
67. Assessment of selective toxicity of insect cell expressed recombinant A1-GMCSF protein toward GMCSF receptor bearing tumor cells. **A. Jahanian-Najafabadi**, S. Bouzari, M. Oloomi, M. Habibi Roudkenar, M.A. Shokrgozar. Research in Pharmaceutical Sciences, August 2012; 7(3)
68. HESA-A Exerts Its Cytoprotective Effects through Scavenging of Free Radicals: An in Vitro Study. Mehryar Habibi Roudkenar, Parisa Bahmani, Raheleh Halabian, Amaneh Mohammadi Roushandeh, **Ali Jahanian-Najafabadi**, Mohammad Ali Shokrgozar. Iran J Med Sci 2012; 37(1): 47-53.
69. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Mohammad Mohammadzadeh, Raheleh Halabian, Ahmad Gharehbaghian, Naser Amirizadeh, **Ali Jahanian-Najafabadi**, Amaneh Mohammadi

Roushandeh and Mehryar Habibi Roudkenar. Cell Stress and Chaperones, 2012 Sep;17(5):553-65.

70. Effects of polygonum aviculare herbal extract on proliferation and apoptotic gene expression of MCF-7. Habibi Roudkenar M., Mohammadi Roushandeh A., Delazar A., Halabian R., Soleimani Rad J., Mehdipour A. Bagheri M., **Jahanian-Najafabadi A**. DARU, 2011;19(5) : 326-331.
71. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI. Mohadeseh Dastpeyman, Nasrin Motamed, Kayhan Azadmanesh, Ehsan Mostafavi, Vahid Kia, **Ali Jahanian-Najafabadi**, Mohammad Ali Shokrgozar, Medical Oncology, 2012 Dec;29(4):2512-8.
72. The Expression of Heme Oxygenase-1 in Human-Derived Cancer Cell Lines. P. Bahmani, G.H. Hassanshahi, R. Halabian, A. Mohammadi Roushandeh, **A. Jahanian-Najafabadi**, M. Habibi Roudkenar. *Iran J Med Sci.* December 2011; Vol 36 No 4.
73. Adenovirus-mediated expression of the HO-1 protein within MSCs decreased cytotoxicity and inhibited apoptosis induced by oxidative stresses, Pejman Hamedi-Asl,Raheleh Halabian,Parisa Bahmani,Mahshid Mohammadipour, Mohammad Mohammadzadeh, Amaneh Mohammadi Roushandeh, **Ali Jahanian-Najafabadi**, Yoshikazu Kuwahara & Mehryar Habibi Roudkenar. Cell Stress and Chaperones, 2012 Mar;17(2):181-90.
74. Genetically engineered mesenchymal stem cells stably expressing green fluorescent protein. Raheleh Halabian, Mohamad Hosein Mohammadi, Mohammad Salimi, Maryam Amani, Amaneh Mohammadi Roushande, Mahnaz Aghaipoor, Nasser Amirizadeh, Majid Ebrahimi, **Ali Jahanian Najafabadi**, Mehryar Habibi Roudkenar. Iranian Journal of Basic Medical Sciences. Vol. 13, No. 2, Spring 2010, 24-30
75. High-level expression of functional recombinant human coagulation factor VII in insect cells. Masroori N, Halabian R, Mohammadipour M, Roushandeh AM, Rouhbakhsh M, **Najafabadi AJ**, Fathabad ME, Salimi M, Shokrgozar MA, Roudkenar MH. Biotechnol let. 2010 Mar 7.
76. Lipocalin 2 regulation by thermal stresses: Protective role of Lcn2/NGAL against cold and heat stresses. Mehryar Habibi Roudkenar, Raheleh Halabian, Amaneh Mohammadi Roushandeh, Mohammad Reza Nourani, Nasser Masroori, Majid Ebrahimi, Mahin Nikogoftar, Mehdi Rouhbakhsh, Parisa Bahmani, **Ali Jahanian Najafabadi**, Mohammad Ali Shokrgozar. Experimental Cell Research 2009; 315: 3140-3151
77. Expression and purification of recombinant human coagulation Factor VII fused to His-Tag through Gateway technology. Raheleh Halabian, Mahdi Edalati Fathabad, Nasser Masroori, Amaneh Mohammadi Roushandeh, Sasan Saki, Nasser Amirizadeh, **Ali Jahanian Najafabadi**, Ahmad Gharehbaghian, Mehryar Habibi Roudkenar. Blood Transfusion 2009; 7: 305-12.
78. Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method. Halabian

R, Roudkenar MH, Esmaeili NS, Masroori N, Roushandeh AM, **Najafabadi AJ**. Vox Sang. 2009 May; 96(4):309-15. Epub 2009 Jan 19.

79. Identification of an isolate of *Pseudomonas aeroginosa* deposited in PTCC as a PHA producer strain: Comparison of three different bacterial genomic DNA extraction methods. Hamid Mir Mohammad Sadeghi , **Ali Jahanian Najafabadi**, Daryoush Abedi, Abbas Jafarian Dehkordi. Journal of Biological Sciences, 2008. 8(4): 826-830.
80. Cloning and partial sequencing of *phaC1* and *phaC2* genes encoding Poly(3-hydroxyalkanoate) synthases from *Pseudomonas aeroginusa* PTCC 1310. Daryoush Abedi, **Ali Jahanian Najafabadi**, Hamid Mirmohammad Sadeghi, Sadeq Vallian. Biotechnology 2007. 6(4): 497-504.

Abstracts:

- Evaluation of Solubility and Production of DT-386BR2 as a Cytotoxic Agent. Taha Safi Ghahderijani**, Ali Jahanian Najafabadi**. 12th Biotechnology congress, 2021, Tehran, Iran.
- Expression and intein mediated purification of P28-IL24 and P28-M4 fusion proteins for targeted cancer therapy, Elahe khodamoradi, **Ali Jahanian Najafabadi**. 12th Biotechnology congress, 2021, Tehran, Iran.
- In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells. **A Jahanian-Najafabadi**, R Ghavimi, V Akbari. Targeted Anticancer Therapy 2020, March 2-5, Paris, France.
- Optimization of recombinant proteins production in Escherichia coli using a two-step chaperones-based system**. Jahanian-Najafanbadi, A**, Sadeghian Rizi, T, Ebrahimi, A. SynBio4. 27-28 May 2019. Waterloo, Canada.
- Introduction of a novel cancer cell targeted fusion protein: DT386-BR2. **A Jahanian-Najafabadi**, F Shafiee, M Rabbani. Targeted Anticancer Therapy 2018, 5-7 March 2018, Paris, France.
- Expression of reteplase by a non-viral insect cell expression system. S. Aflakiyan, H. Mir Mohammad Sadeghi, M. Shokrgozar, M. Rabbani, S. Bouzari, **A. Jahanian-Najafabadi.** 13th Iranian Pharmaceutical Sciences Congress, 2012, Isfahan, Iran.
- Production of recombinant A254-GMCSF immunotoxin by a non-lytic insect cell expression and evaluation of its cytotoxicity by in vitro studies. **A. Jahanian-Najafabadi**, S. Bouzari, M. Oloomi, M. Habibi Roudkenar, M. Shokrgozar. 13th Iranian Pharmaceutical Sciences Congress, 2012, Isfahan, Iran.

Thesis supervision:

- I Supervised more than 50 Pharm. D., and MSc. theses and also 8 Ph.D dissertations.

Positions:

- Deputy dean of post-graduate affairs of the Isfahan Medical University, Aug. 2022 to present.
- Head of university research projects' granting council, Sep. 2019 to present.
- Deputy Dean of Research at Isfahan School of Pharmacy Nov 2021-Nov 2022.
- Deputy dean of post-graduate affairs at Isfahan School of Pharmacy, Nov. 2020- Apr. 2022.
- Deputy Dean of Research at Isfahan School of Pharmacy Jan. 2014 to Feb 2018.
- Head of Pharmaceutical Biotechnology Department, Faculty of Pharmacy, Isfahan University of Medical Sciences, Sep. 2013 to Mar 2018
- Head of university core facility center, Isfahan University of Medical Sciences 2014-2016.

Teaching Experiences

- Molecular Biology and Genetics
- Pharmaceutical Biotechnology: Monoclonal Antibody, Growth Factors and Cytokines, Therapeutic Enzymes and Protein Hormones, Nucleic acids and Cell Based Therapeutics
- Microbial Control of Pharmaceutical Products
- Quality Control of Biopharmaceuticals
- Genetic Engineering and recombinant protein production
- Vaccine production and cancer vaccines
- Bioprocess engineering: Downstream processing
- Baculovirus and insect cell expression systems
- Bioinformatics

Laboratory skills:

- Molecular cloning related techniques
- Cell culture
- *E. coli* expression system
- Baculovirus expression system
- Non-lytic insect cell expression system
- Mammalian Expression system
- Real Time/RT-PCR
- Laboratory Animal handling
- Production and purification of Rabbit polyclonal antibodies

Research IDs:

- https://orcid.org/0000-0001-9538-8260
- https://www.scopus.com/authid/detail.uri?authorId=57216448290
- https://profiles.mui.ac.ir/ali-jahanian-najafabadi
- https://scholar.google.ca/citations?user=v0G-0jgAAAAJ&hl=en